Article (Scientific journals)
Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.
Abizaid, A.; Costa, M. A.; Centemero, M. et al.
2001In Circulation, 104 (5), p. 533-8
Peer Reviewed verified by ORBi
 

Files


Full Text
Circulation-2001-Abizaid-533-8.pdf
Publisher postprint (335.31 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Cerebrovascular Disorders/etiology; Coronary Artery Bypass/adverse effects/economics; Coronary Disease/complications/surgery/therapy; Coronary Vessels/pathology/surgery; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Male; Middle Aged; Myocardial Infarction/etiology; Myocardial Revascularization; Postoperative Complications/mortality; Stents/adverse effects/economics; Survival Analysis; Survival Rate; Treatment Outcome
Abstract :
[en] BACKGROUND: Our aims were to compare coronary artery bypass grafting (CABG) and stenting for the treatment of diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization Therapy Study (ARTS) trial and to determine the costs of these 2 treatment strategies. METHODS AND RESULTS: Patients (n=1205) were randomly assigned to stent implantation (n=600; diabetic, 112) or CABG (n=605; diabetic, 96). Costs per patient were calculated as the product of each patient's use of resources and the corresponding unit costs. Baseline characteristics were similar between the groups. At 1 year, diabetic patients treated with stenting had the lowest event-free survival rate (63.4%) because of a higher incidence of repeat revascularization compared with both diabetic patients treated with CABG (84.4%, P<0.001) and nondiabetic patients treated with stents (76.2%, P=0.04). Conversely, diabetic and nondiabetic patients experienced similar 1-year event-free survival rates when treated with CABG (84.4% and 88.4%). The total 1-year costs for stenting and CABG in diabetic patients were $12 855 and $16 585 (P<0.001) and in the nondiabetic groups, $10 164 for stenting and $13 082 for surgery. CONCLUSIONS: Multivessel diabetic patients treated with stenting had a worse 1-year outcome than patients assigned to CABG or nondiabetics treated with stenting. The strategy of stenting was less costly than CABG, however, regardless of diabetic status.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Abizaid, A.
Costa, M. A.
Centemero, M.
Abizaid, A. S.
Legrand, Victor ;  Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Limet, R. V.
Schuler, G.
Mohr, F. W.
Lindeboom, W.
Sousa, A. G.
Sousa, J. E.
van Hout, B.
Hugenholtz, P. G.
Unger, F.
Serruys, P. W.
More authors (5 more) Less
Language :
English
Title :
Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.
Publication date :
2001
Journal title :
Circulation
ISSN :
0009-7322
eISSN :
1524-4539
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Volume :
104
Issue :
5
Pages :
533-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 01 June 2014

Statistics


Number of views
109 (0 by ULiège)
Number of downloads
1673 (0 by ULiège)

Scopus citations®
 
323
Scopus citations®
without self-citations
303
OpenCitations
 
215

Bibliography


Similar publications



Contact ORBi